We are live on ! Find out more
INTS icon

Intensity Therapeutics

17 hedge funds and large institutions have $4.79M invested in Intensity Therapeutics in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

352% more capital invested

Capital invested by funds: $1.06M → $4.79M (+$3.73M)

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

36.1% more ownership

Funds ownership: 7.15%43.24% (+36%)

21% more funds holding

Funds holding: 1417 (+3)

Holders
17
Holders Change
+3
Holders Change %
+21.43%
% of All Funds
0.2%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.02%
New
4
Increased
4
Reduced
2
Closed
1
Calls
Puts
Net Calls
Net Calls Change

INTS Hedge Fund Activity: Q2 2026 in Review

17 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Intensity Therapeutics (INTS) for Q2 2026, worth a combined $4.79M — up 352% from $1.06M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new INTS positions and 1 closed out — a net gain of 3 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was KMT Wealth Management, opening a new position worth an estimated $2.33M. The largest seller was Geode Capital Management, cutting an estimated $15.2K.

  • 17 institutional investors held Intensity Therapeutics (INTS) as of Q2 2026, up from 14 in Q1 2026.
  • Funds reported $4.79M of Intensity Therapeutics stock for Q2 2026, up 352% quarter-over-quarter.
  • 4 funds opened new Intensity Therapeutics positions in Q2 2026 and 1 closed out, a net change of +3 holders.
  • The largest Intensity Therapeutics buyer in Q2 2026 was KMT Wealth Management, an estimated $2.33M added.
  • The largest Intensity Therapeutics seller in Q2 2026 was Geode Capital Management, an estimated $15.2K sold.

Based on aggregated 13F filings for Q2 2026.